Related Experiment Video

Updated: Dec 8, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

SUMO4 small interfering RNA attenuates invasion and migration via the JAK2/STAT3 pathway in non-small cell lung

Jin-Xiao Liang1, Wei Gao2, Xiao-Wei Zeng1,3

  • 1Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.

Oncology Letters
|September 24, 2020
PubMed

Insights

Small ubiquitin-like modifier 4 (SUMO4) is upregulated in non-small cell lung cancer (NSCLC), correlating with poor prognosis. Inhibiting SUMO4 reduces NSCLC cell invasion, migration, and enhances cisplatin sensitivity by targeting the JAK2/STAT3 pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Small ubiquitin-like modifier 4 (SUMO4) is a key regulator of protein stability and function.
  • The role of SUMO4 in non-small cell lung cancer (NSCLC) remains largely unexplored.
  • Understanding SUMO4's function is crucial for developing novel cancer therapies.

Purpose of the Study:

  • To investigate the expression and function of SUMO4 in NSCLC.
  • To determine the correlation between SUMO4 expression and clinical characteristics in NSCLC patients.
  • To explore SUMO4's potential as a therapeutic target in NSCLC.

Main Methods:

  • Immunohistochemistry was used to assess SUMO4 expression in NSCLC tissues.
  • SUMO4 small interfering RNA (siRNA) was utilized to inhibit SUMO4 expression in NSCLC cell lines.
  • Western blotting, Transwell, wound healing, and Cell Counting Kit-8 assays were performed to evaluate cellular processes and signaling pathways.

Main Results:

  • SUMO4 was found to be upregulated in NSCLC tissues and associated with sex, tumor type, smoking history, T stage, and poor prognosis.
  • SUMO4-siRNA significantly attenuated cell invasion and migration in NSCLC cell lines.
  • SUMO4 inhibition enhanced NSCLC cell chemosensitivity to cisplatin by suppressing the JAK2/STAT3 pathway.

Conclusions:

  • SUMO4 plays a significant role in the progression and poor prognosis of NSCLC.
  • SUMO4 may serve as a potential diagnostic biomarker and therapeutic target for NSCLC.
  • Targeting SUMO4 offers a promising strategy for improving NSCLC treatment outcomes.
Keywords:
JAK2/STAT3 pathwaymetastasisnon-small cell lung cancerprognosissmall ubiquitin-like modifier 4

More Related Videos

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection11:00

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection

Published on: June 23, 2023

2.0K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

658

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.0K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.0K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K